Intelligent Investor

ImpediMed Limited (ASX: IPD) - Share Price and Research

Current share price for IPD : $0.096 0.001 (1.05%)

ImpediMed Limited (IPD), an ASX-listed company, Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

IPD General Information +

ASX Code IPD
Website http://www.impedimed.com
Industry/Sector Health Care Equipment
Market Cap ($M) 194
IPD Share Price $0.096
Day High $0.103
Day Low $0.095
Last Close $0.095
IPD Share Price Movement $0.00 ( 1.05% )
Prices as at 14:30, 19 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
Upsell Banner

IPD Related Research

ImpediMed Limited (IPD) Upcoming Dividends & Yields

There are no dividends for ImpediMed Limited (IPD). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

ImpediMed Limited (IPD) Recent ASX Announcements

Headline Annoucement date/time+ Price at announcement+ Current price+ Price 7D Avg Gain/Loss
Organisational Changes 17 Apr 2024 9:04AM $0.094 $0.096 $0.093 risen by 2.13%
Notification of cessation of securities - IPD 12 Apr 2024 3:28PM $0.092 $0.096 $0.093 risen by 4.35%
Change of Director's Interest Notice - Ms Janelle Delaney 27 Mar 2024 11:51AM $0.086 $0.096 $0.093 risen by 11.63%
  • + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.

See all ASX announcements from ImpediMed Limited (IPD) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.

IPD Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025F C2 -$1.10 -15.40% 0.00 0.00 0.00% 0.0%
2024F C2 -$1.30 14.00% 0.00 0.00 0.00% 0.0%
2023A -$20.52 -$1.10 -3.40% 0.00 0.00 0.00% 0.0%

IPD Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 F 2025 F 2023 A 2024 F 2025 F 2023 A 2024 F 2025 F
Cochlear (COH) $20,843M 0.1063 0.3407 0.1157 68.7225 51.2596 45.9426 1.04% 1.32% 1.52%
Fisher & Paykel Hlth (FPH) $14,366M -0.3337 0.0134 0.3118 61.1180 60.3089 45.9727 1.66% 1.33% 1.47%
Impedimed (IPD) $190M -0.0339 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
ResMed (RMD) $17,929M 0.1879 0.0960 0.1089 31.3130 28.5714 25.7650 0.71% 0.95% 1.05%

IPD Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 3.15 0.00
Market 0.65 16.60 1.40 1.29
Sector 0.84 33.30 2.35 2.42

IPD Directors

Name Position Start Date
Mr McGregor Grant Executive Chairman, Executive Director, Interim CFO 28 Sep 2023
Dr Parmjot Bains Managing Director, Interim CEO 8 Jan 2024
Mr Andrew John Grant Non-Executive Director 28 Sep 2023
Ms Christine Emmanuel-Donnelly Non-Executive Director 28 Sep 2023
Ms Janelle Delaney Non-Executive Director 28 Sep 2023

ImpediMed Limited (IPD) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
25 Mar 2024 DELANEY, Janelle Buy Indirect Shares 568,181 $0.088 $49,999.928
22 Mar 2024 DELANEY, Janelle Buy Indirect Shares 581,395 $0.086 $49,999.970
4 Mar 2024 DELANEY, Janelle Buy Indirect Shares 1,137,634 $0.088 $99,591.035

See all changes in directors' interest & trades for ImpediMed Limited (IPD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IPD Management

Name Position
Timothy Cruickshank Chief Financial Officer
Shashi Tripathi Chief Operating Officer
Joann Yao Chief Strategy Officer
Leanne Ralph Company Secretary
Dennis Schlaht Senior Vice President R&D and Technology
Lisa Prom Vice President, Sales

IPD Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in ImpediMed Limited (IPD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
144,301,807 (7.15%) Paradice Investment Management Pty Ltd
122,513,808 (6.07%) National Nominees Ltd

IPD Calendar of Events

Date Event
25 February 2025 Report (Interim)
29 August 2024 Report (Annual)
29 August 2024 Report (Prelim)

FAQs about ImpediMed Limited (IPD)

ImpediMed Limited's (IPD) current share price is $0.10. This constitutes a price movement of 3.23% when compared to the share price 7 days ago and is -58.26% below IPD's 12-month high of $0.23 per share. Prices are delayed by at least 20 minutes.

Relative to the previous close share price of $0.10, ImpediMed Limited's (IPD) current share price of $0.10 constitutes a movement of $0.00 or 1.05%. ImpediMed Limited's (IPD) share price movement is 3.23% when compared to 7 days ago and is -58.26% below IPD's 52-week high of $0.23.

ImpediMed Limited's (IPD) 52-week high is $0.23 which was reached on 19 Jul 2023. Relative to this, IPD's current share price of $0.10 constitutes a -$0.13 or -58.26% drop since that high of $0.23 per IPD share.

ImpediMed Limited's (IPD) 52-week low is $0.08 which was reached on 12 Feb 2024. Relative to this, IPD's current share price of $0.10 constitutes a $0.02 or 24.68% gain since that low of $0.08 per IPD share.

Over the last 12 months, ImpediMed Limited (IPD) has a daily average trading volume of 3,074,121 IPD shares per day.

ImpediMed Limited (IPD) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for IPD is a ratio that tells you the percentage of ImpediMed Limited's (IPD) share price that it pays out in dividends each year.

ImpediMed Limited (IPD) has a franking level of 0%. Franking represents the tax ImpediMed Limited (IPD) has already paid on any profit it distributes to shareholders as a dividend.

ImpediMed Limited (IPD) will release its next Annual Report on 29 August 2024. ImpediMed Limited's (IPD) last annual report was released on 31 Aug 2023. Click here to view ImpediMed Limited's (IPD) last annual report.

ImpediMed Limited (IPD) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).

The price-to-earnings (P/E) ratio for ImpediMed Limited (IPD) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of ImpediMed Limited's (IPD) share price to its earnings per IPD share.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.